Choose an applicable source.
Do not create a blended dose.

Check the monitoring plan, not just the renal dose.

Each prompt links to newly stored, separately attributed evidence. These are review aids, not patient-specific prescriptions.

Check the boundary, formulation and next clinical question.

These selected findings link to their local source cards and dated comparisons. They do not calculate a patient dose or establish independent approval.

The finding, its scope and its date.

Read the finding in its clinical setting.

Read the product, the setting and the boundary.

The new usage guide explains the evidence navigator and medication-list workflow. These selected clinical questions remain linked to their actual sources and await independent adjudication.

Find the source, then confirm what it supports

Each drug now has prominent source buttons. The medication-list screen keeps entered drugs first, requires confirmation of spelling suggestions and does not infer a dose. An unmatched or unshaded drug is not a no-adjustment finding.

Check the question the renal source actually answers

These links open the attributed source summaries and review notes. They are review prompts, not a new combined regimen or independent clinical approval.

Ask the question that makes a source applicable

The clinical review-check finder links 175 practical questions to the exact stored source cards. It distinguishes actual guideline deviations from differences caused by indication, product, renal measure or missing evidence.

Examples include standalone EMTRIVA versus NIH guidance, ELEPSIA XR versus other levetiracetam products, exenatide release formulations, ERZOFRI initiation, and a DMD creatinine-estimation limitation. These checks are selected examples, not an exhaustive patient-specific safety checklist.

Product and source checks that change how you read a renal statement

Examples link to local source cards and locators. Independent clinical review remains pending. No patient identifiers should be entered into search or URL fields.

New: do not lose older sources when filtering by renal measure

Select a renal measure in the Clinical-focus finder and optionally include unclassified sources. Results distinguish label matches from sources that still need manual interpretation. The original cards and pinned review fingerprints are unchanged.

Unclassified does not mean no renal adjustment, no renal measure or poor evidence. ITOVEBI is an example with named CKD-EPI but ambiguous printed units; older cards may simply lack the new classification field. Other filters still restrict results. Broaden clinical topic or source family as needed.

Keep the reason for a difference visible

Ifosfamide illustrates indication-specific institutional guidance: the Ewing IE and lymphoma RICE protocols do not make identical recommendations in severe kidney impairment. Ertapenem illustrates dialysis-schedule differences and printed boundary ambiguity. Neither case is resolved by averaging regimens.

NeoProfen illustrates a neonatal withholding rule: the birth-weight course and urine-output trigger belong to premature infants with PDA, not to adult ibuprofen dosing. Read the entire stored source and current prescribing information before use.

New: match the renal measure before matching the dose band

The source-family filter now works with a renal-measure filter. Measure labels were assigned to selected v4.2/v4.3/v4.4 source text. Older cards remain unclassified until checked; this is not evidence that their guidance lacks a renal measure.

Filters describe source wording, not a quality rank or prescribing approval. Keep dose, interval, renal method, formulation and monitoring from the same applicable source together.

Earlier comparison examples retained

Each is a selected-source interpretation pending independent clinician review. The full prescribing context remains necessary.

Find another source perspective without counting mirrors twice

The clinical-focus finder now filters the stored source family: official-label summaries, RX List label mirrors, professional/research/regulatory material, handbooks, or preserved original GlobalRPh text. The family describes where the stored content comes from, not its quality, currency or independent agreement.

Use a family filter to find a professional perspective beside a label. Then open the complete source and compare indication, formulation, renal measure, timing and monitoring. Two mirrors of the same label are not two independent confirmations. An institutional regimen can be off-label or indication-specific.

A narrow family or topic filter can hide a relevant qualification. Clear filters or use the all-text search before concluding that guidance is missing. No-adjustment wording does not remove monitoring requirements. Never enter patient identifiers into these server-side search fields.

Find a clinical topic without turning a filter into a recommendation

The clinical-focus finder groups locally stored source summaries by their authored content labels: dosing, restrictions, monitoring, qualified no-adjustment statements, pharmacokinetic observations, historical safety context and evidence gaps. New v4.1 summaries have manually assigned multi-topic labels. Earlier summaries use their existing content category; many remain unclassified. Original GlobalRPh sections remain available as unclassified preserved material.

These labels describe selected text, not evidence quality or every possible effect of a drug. Search the complete library when a narrow filter finds nothing. A qualified no-adjustment statement applies only to its stated product, renal range, indication and population. It is not permission to ignore toxicity, interactions, dialysis or monitoring.

Each result links to the full stored source and a shareable source review retaining drug-level warnings. No source is ranked, no patient data is entered and no regimen is calculated. Filters are normal server search parameters: never enter patient identifiers.

Share the exact sources, not a blended regimen

Open a drug and choose one or two source cards for a print-ready review. The page keeps product scope, renal method, source date, retrieval status and record cautions beside the selected text. Use its pinned link to preserve the local card identities and fingerprints. If a pinned card later changes or disappears, the page stops and asks for a fresh selection instead of substituting another source.

The link includes only the drug ID, source IDs and local-card fingerprints. It does not include patient information or a recommended dose. The treating team must document the clinical decision in its approved system. Fingerprints identify local cards, not original label files and not clinical approval.

Find and classify a disagreement before choosing a regimen

Use the cross-drug difference directory to search a generic name, brand, source organization or issue. Filter to a category or to additions in this release. Each result keeps the actual drug, source identities, source dates and the documented action together.

First ask whether the recommendations truly conflict. Different routes, indications, populations, renal measures, dialysis prescriptions or interacting drugs can explain the difference. A source-quality failure or historical regulatory warning is not an alternative regimen to select.

Open the drug page to compare the complete stored source summaries. The directory does not rank a winning dose, certify independent agreement or replace current source and local-policy review. No result means no documented note was found, not that the sources agree. Do not enter patient information in directory searches.

A practical reading sequence

Focus on one source without losing the other evidence

The source selector limits finder highlights to all stored text, the preserved original, or one named source. It never removes source cards, source warnings or comparison notes. Search a literal term such as dialysis, CrCl or eGFR; Previous and Next identify the source containing each match. Switching scope reruns the current search.

Zero matches only means those exact words were absent in the selected excerpts. It does not establish no adjustment, safety, agreement or a full review. Enter advances, Shift+Enter reverses and Escape clears. Search terms and scope are neither stored nor transmitted by this feature.

v3.7: questions worth documenting before a regimen is chosen

These examples link to locally stored source summaries, locators and citations. New clinical interpretations remain pending independent clinician review. No dose is selected by the interface.

Retained comparison examples for clinical review

These examples link to the locally stored source summaries and their citations. Each remains pending independent clinical adjudication.

How to interpret opposing recommendations

Do not average the doses, select the lowest number automatically, or combine one source's dose with another source's interval. Source count is not a vote, and a label mirror is not independent corroboration.

Absence of a difference note does not establish agreement. The twelve notes added in v3.6 were selected findings, not a complete conflict-detection audit.

Evidence status you can inspect

Imported: the selected clinical text is physically included and can be read without a source-site request. Rechecked: selected source sections were inspected during the identified release. Independent clinical validation: a separate adjudication process, not implied by either of the first two statuses.

New content is pending independent clinical review. The entire RX List A-Z monograph review and a verified Google/Bing top-100 ranking remain incomplete. Historic sources, failed retrievals and scope limits are shown rather than converted into guessed regimens.

Separate a dose instruction from a renal observation

New source cards identify dose guidance, restrictions, qualified no-adjustment statements, pharmacokinetic findings, monitoring and unstudied populations. A badge describes the selected text; it is not an evidence-quality score or complete product review.

Do not interpret a missing renal schedule as no adjustment. Conversely, an adverse-event warning can be important even when the source does not change the dose.

Document the reason for a difference

The source-review outline on a drug page includes chosen source identities, renal methods, dates and empty decision fields. It contains no automatically selected dose and is not a completed patient note. Complete the indication, renal setting, rationale, monitoring and reassessment in your approved system.

A concrete protocol disagreement

The two locally stored eviQ capecitabine protocols use different recommendations at the same eGFR band. Choose by the cancer setting and protocol, rather than treating the two pages as independent corroboration or averaging the regimens.

What remains before a directory is complete

Discovery, attempts, retrieval, selected-section import, full-monograph review and independent clinical sign-off are separate steps. Current entry-attempt logs cover F, G, H, I, J, K, Q, U, V, W, X, Y and Z. The prior I/F exact-link backlogs are reconciled, but other retrieval and review gaps remain. No letter has completed every later clinical-review step.

Source basis

The interpretation examples link directly to the separately attributed local drug cards. Renal-measure, dynamic-function and dialysis context comes from the three preserved methods summaries, recheck status shown in the source audit. Previously added perspectives include the 2023 AGS Beers Criteria and the 2022 ADA/KDIGO consensus; neither is labeled here as the latest guideline edition.

Reviewed source URLs, section locators, known source dates, retrieval dates and local-summary hashes are included with each card. Original complete source HTML, PDF and SPL XML files are not bundled. Clinical application remains the responsibility of the treating team.